23andme's prospects for survival dim

The data's going to be sold, isn't it?

Image: 23andme

Genetic surveillance company 23andMe, once a $6bn prospect, is now a penny stock on the verge of doom. So "what happens to all its DNA data?" asks NPR.

As 23andMe struggles for survival, customers like Wiles have one pressing question: What is the company's plan for all the data it has collected since it was founded in 2006?

"I absolutely th…